Short telomere length in peripheral blood leukocyte predicts poor prognosis and indicates an immunosuppressive phenotype in gastric cancer patients

Molecular Oncology

Volumn 9, Issue 3, 2015, Pages 727-739

  Qu, Falin ^a   Li, Renli ^a   He, Xianli ^a   Li, Qiucheng ^a   Xie, Shuang ^a   Gong, Li ^a   Ji, Gang ^b   Lu, Jianguo ^a   Bao, Guoqiang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Leukocyte telomere length; Prognosis; Regulatory B lymphocyte

Indexed keywords

CD19 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; FEMALE; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RELATIVE TELOMERE LENGTH; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; TELOMERE HOMEOSTASIS; BLOOD; DISEASE FREE SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; PATHOLOGY; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH TUMOR; TELOMERE; TELOMERE SHORTENING; TUMOR RECURRENCE;

CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; KAPLAN-MEIER ESTIMATE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TELOMERE; TELOMERE SHORTENING;

EID: 84923534074     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.11.008     Document Type: Article

References (45)

1. Amedei A., Benagiano M., della Bella C., Niccolai E., D'Elios M.M. Novel immunotherapeutic strategies of gastric cancer treatment. J.Biomed. Biotechnol. 2011, 2011:437348.
2. Amedei A., Munari F., Bella C.D., Niccolai E., Benagiano M., Bencini L., Cianchi F., Farsi M., Emmi G., Zanotti G., de Bernard M., Kundu M., D'Elios M.M. Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. Intern. Emerg. Med. 2014, 9:303-309.
3. Bailey S.M., Murnane J.P. Telomeres, chromosome instability and cancer. Nucleic Acids Res. 2006, 34:2408-2417.
4. Bisoffi M., Heaphy C.M., Griffith J.K. Telomeres: prognostic markers for solid tumors. Int. J. Cancer 2006, 119:2255-2260.
5. Bohlen H., Kessler M., Sextro M., Diehl V., Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann. Hematol. 2000, 79:110-113.
6. Chau G.Y., Wu C.W., Lui W.Y., Chang T.J., Kao H.L., Wu L.H., King K.L., Loong C.C., Hsia C.Y., Chi C.W. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann. Surg. 2000, 231:552-558.
7. Chen T., Song D., Min Z., Wang X., Gu Y., Wei B., Yao J., Chen K., Jiang Z., Xie H., Zhou L., Zheng S. Perioperative dynamic alterations in peripheral regulatory T and B cells in patients with hepatocellular carcinoma. J.Transl. Med. 2012, 10:14.
8. Chen Y., Qu F., He X., Bao G., Liu X., Wan S., Xing J. Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients. Ann. Oncol. - Off. J. Eur. Soc. Med. Oncol./ESMO 2014, 25:869-876.
9. Damjanovic A.K., Yang Y., Glaser R., Kiecolt-Glaser J.K., Nguyen H., Laskowski B., Zou Y., Beversdorf D.Q., Weng N.P. Accelerated telomere erosion is associated with a declining immune function of caregivers of Alzheimer's disease patients. J.Immunol. 2007, 179:4249-4254.
10. Edge S., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC Cancer Staging Manual 2009, 117-126. Springer-Verlag, New York. seventh ed.
11. Effros R.B. Telomere/telomerase dynamics within the human immune system: effect of chronic infection and stress. Exp. Gerontol. 2011, 46:135-140.
12. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
13. Gramatges M.M., Telli M.L., Balise R., Ford J.M. Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. Cancer Epidemiol. Biomarkers Prev. - A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2010, 19:605-613.
14. Hodes R.J., Hathcock K.S., Weng N.P. Telomeres in T and B cells. Nat. Rev. Immunol. 2002, 2:699-706.
15. Hou L., Savage S.A., Blaser M.J., Perez-Perez G., Hoxha M., Dioni L., Pegoraro V., Dong L.M., Zatonski W., Lissowska J., Chow W.H., Baccarelli A. Telomere length in peripheral leukocyte DNA and gastric cancer risk. Cancer Epidemiol. Biomarkers Prev. - A Publication of theAmerican Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2009, 18:3103-3109.
16. Hou L., Zhang X., Gawron A.J., Liu J. Surrogate tissue telomere length and cancer risk: shorter or longer?. Cancer Lett. 2012, 319:130-135.
17. Hu H., Zhang Y., Zou M., Yang S., Liang X.Q. Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer. J.Cancer Res. Clin. Oncol. 2010, 136:1407-1414.
18. Hug N., Lingner J. Telomere length homeostasis. Chromosoma 2006, 115:413-425.
19. Iwama H., Ohyashiki K., Ohyashiki J.H., Hayashi S., Yahata N., Ando K., Toyama K., Hoshika A., Takasaki M., Mori M., Shay J.W. Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum. Genet. 1998, 102:397-402.
20. Jang J.S., Choi Y.Y., Lee W.K., Choi J.E., Cha S.I., Kim Y.J., Kim C.H., Kam S., Jung T.H., Park J.Y. Telomere length and the risk of lung cancer. Cancer Sci. 2008, 99:1385-1389.
21. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
22. Jung S.W., Park N.H., Shin J.W., Park B.R., Kim C.J., Lee J.E., Shin E.S., Kim J.A., Chung Y.H. Prognostic impact of telomere maintenance gene polymorphisms on hepatocellular carcinoma patients with chronic hepatitis B. Hepatology 2014, 59:1912-1920.
23. Lan Q., Cawthon R., Shen M., Weinstein S.J., Virtamo J., Lim U., Hosgood H.D., Albanes D., Rothman N. A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma. Clin. Cancer Res. - Off. J. Am. Assoc. Cancer Res. 2009, 15:7429-7433.
24. Liu H.Q., An J.Z., Liu J., Yang Y.F., Zhang H.X., Zhao B.Y., Li J.B., Yang H.S., Chen Z.N., Xing J.L. Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization. Carcinogenesis 2012, 33:1040-1045.
25. Liu J., Yang Y., Zhang H., Zhao S., Liu H., Ge N., Yang H., Xing J.L., Chen Z. Longer leukocyte telomere length predicts increased risk of hepatitis B virus-related hepatocellular carcinoma: a case-control analysis. Cancer 2011, 117:4247-4256.
26. Liu X., Bao G., Huo T., Wang Z., He X., Dong G. Constitutive telomere length and gastric cancer risk: case-control analysis in Chinese Han population. Cancer Sci. 2009, 100:1300-1305.
27. Maruyama Y., Hanai H., Fujita M., Kaneko E. Telomere length and telomerase activity in carcinogenesis of the stomach. Jpn. J. Clin. Oncol. 1997, 27:216-220.
28. Mauri C., Bosma A. Immune regulatory function of B cells. Annu. Rev. Immunol. 2012, 30:221-241.
29. Milne A.N., Carneiro F., O'Morain C., Offerhaus G.J. Nature meets nurture: molecular genetics of gastric cancer. Hum. Genet. 2009, 126:615-628.
30. Mooi W.J., Peeper D.S. Oncogene-induced cell senescence - halting on the road to cancer. N.Engl. J. Med. 2006, 355:1037-1046.
31. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
32. Mougiakakos D., Choudhury A., Lladser A., Kiessling R., Johansson C.C. Regulatory T cells in cancer. Adv. Cancer Res. 2010, 107:57-117.
33. Murnane J.P. Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res. 2010, 70:4255-4259.
34. Schioppa T., Moore R., Thompson R.G., Rosser E.C., Kulbe H., Nedospasov S., Mauri C., Coussens L.M., Balkwill F.R. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10662-10667.
35. Shao L., Wood C.G., Zhang D., Tannir N.M., Matin S., Dinney C.P., Wu X. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J.Urol. 2007, 178:1492-1496.
36. Svenson U., Gronlund E., Soderstrom I., Sitaram R.T., Ljungberg B., Roos G. Telomere length in relation to immunological parameters in patients with renal cell carcinoma. PLoS One 2013, 8:e55543.
37. Svenson U., Ljungberg B., Roos G. Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res. 2009, 69:2896-2901.
38. Svenson U., Nordfjall K., Stegmayr B., Manjer J., Nilsson P., Tavelin B., Henriksson R., Lenner P., Roos G. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res. 2008, 68:3618-3623.
39. Svenson U., Roos G. Telomere length as a biological marker in malignancy. Biochim. Biophys. Acta 2009, 1792:317-323.
40. von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann. N. Y. Acad. Sci. 2000, 908:99-110.
41. Wang H.Y., Wang R.F. Regulatory T cells and cancer. Curr. Opin. Immunol. 2007, 19:217-223.
42. Weng N.P. Telomeres and immune competency. Curr. Opin. Immunol. 2012, 24:470-475.
43. Wentzensen I.M., Mirabello L., Pfeiffer R.M., Savage S.A. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. - A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2011, 20:1238-1250.
44. Yasui W., Oue N., Aung P.P., Matsumura S., Shutoh M., Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer - Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc. 2005, 8:86-94.
45. Zlobec I., Vuong T., Hayashi S., Haegert D., Tornillo L., Terracciano L., Lugli A., Jass J. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br. J. Cancer 2007, 96:793-800.